| Bioactivity | BMS-1233 is an orally active inhibitor for programmed cell death-ligand 1 (PD-L1), with IC50 of 14.5 nM. BMS-1233 promotes cell death of HepG2 in a Jurkat T cell and HepG2 cell co-culture model, exhibits antitumor activity against melanoma in mouse model[1]. |
| CAS | 2447065-99-6 |
| Formula | C35H33ClN2O4 |
| Molar Mass | 581.10 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Cheng B, et al., Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment. Signal Transduct Target Ther. 2023 Mar 1;8(1):91. |
BMS-1233
CAS: 2447065-99-6 F: C35H33ClN2O4 W: 581.10
BMS-1233 is an orally active inhibitor for programmed cell death-ligand 1 (PD-L1), with IC50 of 14.5 nM. BMS-1233 promot
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.